Subscribe
gavel-pills-istock-525883642-vnphotolab-
AVNphotolab / iStockphoto.com
27 September 2018Americas

Brazilian court suspends Gilead patent after presidential candidate request

A Brazilian federal judge has granted a preliminary injunction against a patent for US-based Gilead’s Sovaldi (sofosbuvir) drug, used to treat hepatitis C, following a complaint by a presidential candidate.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

More on this story

Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

More features

Could Apple v Masimo limit patent cases at the ITC?
Eli Lilly strikes again in weight-loss drugs fight
Novartis moves to block cancer drug generic in US
WATCH: China patent landscape—AI, patent linkage, export controls, and more
China bars USPTO employee from leaving country
UPC hands rare default win to Insulet, bans insulin pump in EU
GSK loses appeal over purple inhaler TM in Europe
Astellas defends Xtandi patent as court rejects generics’ appeal